Gilead Sciences, Inc. (GILD) stock analysis

Gilead Sciences, Inc. — Healthcare · Drug Manufacturers—General carries a Plainview business-quality score of 7.9/10, built deterministically from SEC filings and Yahoo Finance: revenue, margins, cash, valuation, and a confluence buy zone. The live X-Ray loads below.

On the fundamentals, Gilead Sciences, Inc. shows trailing revenue of $29.74B, a 79.4% gross margin, net debt of $12.23B, EPS of 6.72, valued at about 5.5x times sales. X-Ray measures business quality only — momentum and entry timing live in Decide and Opportunity Cost.

• Current Price: $132.73
• YTD Return: +9.2%
• Revenue TTM: $29.74B
• Revenue Trend: YoY +4.4%
• Gross Margin: 79.4%
• Net Cash: $-12.23B
• EPS: 6.72
• P/S Ratio: 5.5x

Compare: GILD vs UNH · GILD vs JNJ · GILD vs LLY | Also: UNH, JNJ, LLY, PFE, MRK, ABBV